Background and objective: The diagnostic classification of 'possible idiopathic pulmonary fibrosis (posIPF)' is characterized by a radiological pattern of inconsistent usual interstitial pneumonia (UIP) on high-resolution computed tomography (HRCT) scan and a UIP pattern in surgical lung biopsy (SLB). The evidence base to guide treatment for patients with posIPF is lacking; the clinician must choose between observation, treatment with immunomodulatory agents or anti-fibrotic agents. Methods: To evaluate outcomes of immunomodulatory treatment, a multicentre cohort of 59 posIPF patients treated with prednisone was analysed retrospectively. Prednisone starting dose was 0.5 mg/kg/day and tapered to 0.15 mg/day/kg over 6 months. Outcome measures were forced vital capacity (FVC) and serious adverse events (SAE), defined as death or hospital admissions. Results: The majority of prednisone-treated posIPF patients were non-responders (68%) with a decrease in FVC >5% or death within 6 months from baseline; 90% of patients with radiographical presence of honeycombing were non-responders. In contrast, six out of seven patients with focal desquamative interstitial pneumonialike reaction in the SLB who had stopped smoking for <5 years ago were responders to prednisone, demonstrating <5% FVC decline. The mean decline of FVC was 8.7% (95% CI: 3.1-14.3%) before treatment and 20% (95% CI: 9.4-31.1%) after treatment (P = 0.018) in the 32 patients with available FVC data. Twelve SAE occurred within the first 3 months on prednisone (at dosage >0.3 mg/kg/day), including five deaths. Conclusion: Patients with posIPF demonstrated an accelerated FVC decline and a substantial number of SAE on steroid therapy.
INTRODUCTION
Idiopathic pulmonary fibrosis (IPF) is a chronic progressive fibrotic lung disease of unknown cause with limited treatment options. 1 Within the group of idiopathic interstitial pneumonias (IIP), IPF is the most common disease with a median survival of approximately 3 years. 2 The diagnosis of IPF is based on the absence of a known cause of lung fibrosis, highresolution computed tomography (HRCT) findings of a usual interstitial pneumonia (UIP) pattern and, when necessary, pathological observation of a UIP pattern. However, HRCT patterns inconsistent with UIP, such as non-classifiable or non-specific interstitial pneumonia (NSIP), are commonly found 3 and provide a challenge for both diagnosis and management. In patients
SUMMARY AT A GLANCE
Evidence is lacking to guide treatment of patients with suspected idiopathic pulmonary fibrosis (IPF) who have radiological inconsistent usual interstitial pneumonia (UIP) and UIP pattern in surgical lung biopsy. In this retrospective cohort, these patients demonstrated an accelerated decline in forced vital capacity (FVC) and multiple serious adverse events when treated with prednisone.
with a radiological pattern inconsistent with UIP, a biopsy is recommended. When a histopathological pattern of UIP is found on biopsy, a diagnosis of 'possible IPF' (posIPF) is made. 1, 2 Further classification and therapeutic decision-making in patients with conflicting radiological and pathological patterns, like posIPF, largely rely on multidisciplinary discussion. 1, 2 Despite substantial mortality, 4 little is known about therapeutic management in patients diagnosed with posIPF.
Most patients with progressive non-IPF are treated with immunomodulatory agents such as prednisone, azathioprine or cyclophosphamide to stabilize or slow down the disease process. [5] [6] [7] [8] The pathogenic mechanism in IPF is not driven by inflammation 9 and the combination therapy of prednisone, azathioprine and N-acetylcysteine was shown to be detrimental on mortality and hospitalization. 10 Recently, two landmark studies of anti-fibrotic treatments demonstrated a deceleration in the deterioration of forced vital capacity (FVC) in IPF. 11, 12 This resulted in a recommendation for pirfenidone and nintedanib in the updated IPF guidelines. 13 The Assessment of Pirfenidone to Confirm Efficacy and Safety in Idiopathic Pulmonary Fibrosis (ASCEND) trial with pirfenidone did not include posIPF patients. The INPULSIS-1 and INPULSIS-2 trials with nintedanib included only 2.5% of posIPF patients. 12, 14 Given the relatively small size of this posIPF subgroup, this could not have had a large impact on the final results; this group was not separately analysed. Therapeutic implications are relevant for the definitive diagnostic category of IPF patients. 15 The updated ATS/ERS 2015 IPF guidelines referred to these trials and made no recommendations for posIPF patients. 13 In patients with posIPF, the multidisciplinary team will have to consider ongoing observation and a trial of immunomodulatory therapy or anti-fibrotic therapy with a working diagnosis of IPF. Although this dilemma is recognized, no research has been conducted on therapeutic management in this category of patients. In this international, multicentre, retrospective study, we report our experience with a 6-month treatment of prednisone in patients with posIPF.
METHODS

Patient selection
A review of all patients with interstitial lung disease (ILD) diagnosed at St Antonius Hospital Nieuwegein and University Hospital (UZ) Leuven between November 2005 and April 2015 was performed. Criteria for posIPF were an IIP with an inconsistent UIP pattern on HRCT scan and a histological UIP pattern in surgical lung biopsy (SLB). 1 In patients diagnosed before 2011 with a histological UIP pattern, an experienced ILD radiologist reviewed the HRCT scan and only patients with HRCT characteristics inconsistent with UIP were included. Consecutive patients classified as posIPF were included when a trial of oral prednisone intended for a period of 6 months was initiated.
Demographic characteristics and medical information were retrieved from hospital records. Patients without IIP and patients with familial interstitial pneumonitis were excluded. All SLB were performed with a video-assisted thoracoscopic surgery. In all but two patients, the SLB were taken from ≥2 lung lobes to diminish the sampling error. 16, 17 Concomitant histopathological patterns of desquamative interstitial pneumonia (DIP) and accumulation of macrophages in alveolar spaces were noted. These DIP-like features were described as focal and not the predominant histological pattern. The study was approved by the local institutional review board of St Antonius Hospital Nieuwegein (registration number R05-08A and W14.056).
Prednisone trial treatment
Data regarding prednisone treatment were retrieved from hospital records. Baseline was defined as starting date of the oral prednisone regimen, which started mostly at 0.5 mg/kg/day. For 6 months, there was a monthly reduction in the dose of prednisone and it was finally tapered to approximately 0.15 mg/kg/day. Patients were excluded if they had received any immunomodulatory therapy prior to initiation of the prednisone. At St Antonius hospital prednisone was used, while at UZ Leuven prednisolone was used. For convenience, in this article, we utilized the term prednisone to include both prednisone and prednisolone treatment.
Pulmonary function tests and SAE
FVC data were retrieved 4-11 months prior to therapy, at baseline (start of therapy) and 6 AE 2 months after the start of therapy. In 38 of 140 patients, pulmonary function tests (PFT) were collected from the referring hospitals. Changes in FVC were extrapolated to 6 months before the initiation of prednisone. Serious adverse events (SAE) were defined as death or hospital admission. Post-treatment FVC of patients who died within 6 months was defined as 0, similar to the methodology in the ASCEND trial. 11 Analyses were based on survival and non-survival.
Therapy effect was described as responders and nonresponders. Responders were defined as patients with stabilization of <5% FVC decline or improvement in 6 months after the start of therapy. Non-responders were defined as patients with >5% FVC decline or death within 6 months from baseline.
Statistical analysis
Percentage change in FVC before and after prednisone treatment was analysed with the Wilcoxon signed rank test. Chi-square or Fisher's exact test, when appropriate, were conducted to analyse differences in response between groups. A P-value of <0.05 was considered as statistically significant. Analyses were conducted with IBM SPSS statistics software for Windows (version 22.0; IBM, Armonk, NY, USA) and Graphpad PRISM 5 -(GraphPad Software, La Jolla, CA, USA).
RESULTS
Baseline characteristics
Of the 2945 patients with IIP in our databases, 140 were diagnosed with posIPF and a total of 59 posIPF patients were treated with prednisone, 39 from St Antonius Hospital and 20 from UZ Leuven ( Table 1) . At treatment initiation, patients had pulmonary impairment with a mean FVC of 73% predicted and a mean diffusing capacity of the lungs for carbon monoxide of 42% predicted.
The HRCT scans of posIPF patients were characterized as inconsistent with UIP, mainly because of an upper or a mid-lung predominance of reticulation (70%). A considerable number of patients demonstrated honeycombing (45%) (Fig. 1) . Fibroblast foci were demonstrated in all biopsies consistent with a UIP. In addition, 14 patients had concomitant focal DIP-like features (Table 2 ). 
Responders and non-responders
Analysis of responsiveness to prednisone treatment was performed with 47 patients (Table 2) . In 12 patients, no FVC data were available after 6 months because they were lost to follow-up. The majority of patients did not respond to therapy (32/47, 69%) and experienced deterioration of >5% FVC; all demonstrated >100 mL absolute FVC decline or died within 6 months from baseline.
Significant differences in gender, HRCT and concomitant histological pattern were observed (Table 2) . Nearly all patients (90%) with honeycombing on HRCT did not respond to prednisone therapy (P = 0.004). However, female patients (10/18) were more likely to respond than male patients (5/24, P = 0.006). Moreover, presence of a concomitant focal DIP-like pattern in addition to UIP on SLB was associated with positive response to therapy (P = 0.034). This was mainly observed in patients who stopped smoking <5 years ago (range 2 months-3 years, n = 7, P = 0.003), and only observed in five patients who never smoked or stopped smoking >5 years ago (n = 5, P = 1, range of smoking cessation 8-40 years) (Fig. 3A) .
Other baseline characteristics such as age, PFT and immunological bronchoalveolar lavage (BAL) data were not different between responders and non-responders.
Change in pulmonary function
Analysis of FVC change before and after prednisone treatment was performed with 32 patients. Their baseline characteristics were not significantly different from the 27 patients with missing FVC data at set time points.
In the 6-month period before the start of treatment, the mean decline in FVC was 8.7% (95% CI: 3.1-14.3%). Six months after the start of prednisone treatment, the mean FVC decline was 20.3% (95% CI: 9.4-31.1%, P = 0.018); this included the FVC of 0 mL after 6 months for deceased patients (Fig. 3B) . Analysing only the 29 patients still alive after 6 months resulted in a mean FVC decline of 8.2% (95% CI: 2-14.3%) before and 12.9% (95% CI: 6-18.1%) after the start of prednisone treatment (P = 0.086; Fig. 3C ).
Further exclusion of patients with concomitant focal smoking-related histopathological features on biopsy who stopped smoking <5 years before the initiation of prednisone (n = 5, with the available FVC data) resulted in a cohort of 24 posIPF patients treated with prednisone. Analysis of the surviving patients showed a decline in FVC of 7.7% (95% CI: 1.1-14%) before treatment and 14.9% (95% CI: 8.3-21.6%, P = 0.021, Fig. 3D ) 6 months after treatment initiation.
Serious adverse events
Fourteen SAE occurred during 6 months of prednisone treatment and are displayed by month in Figure 4 . The majority (71%) had an infectious cause and 80% of the SAE occurred within the first 3 months with a Responders were defined as patients with <5% FVC decline or FVC improvement; non-responders defined as patients with death or >5% FVC decline during 6 months of prednisone treatment.
BAL, bronchoalveolar lavage; DL CO , diffusing capacity of the lungs for carbon monoxide; DIP, desquamative interstitial pneumonia; FVC, forced vital capacity.
prednisone dose of ≥0.3 mg/kg/day. Five patients died and seven had hospital admission within 3 months after the initiation of prednisone.
DISCUSSION
This retrospective study showed that patients with posIPF have an accelerated FVC decline and high occurrence of SAE after the initiation of prednisone treatment. Interestingly, female gender or presence of concomitant DIP histopathological pattern appeared to be associated with initial positive responsiveness to prednisone treatment. These results suggest that clinicians should be cautious in considering a trial of prednisone treatment in posIPF patients.
According to the current international diagnostic criteria, patients in the category of posIPF have an HRCT inconsistent with UIP and biopsy with predominant UIP features. They pose diagnostic and therapeutic challenges for multidisciplinary ILD teams. To our knowledge, this is the first study to specifically study the effect of prednisone treatment in posIPF patients. The majority (69%) of posIPF patients were non-responders and had >5% FVC decline after 6 months of prednisone.
SAE were most frequently (80%) observed during the first 3 months of prednisone treatment, while patients were receiving a relatively high dose of prednisone (>0.3 mg/kg/day). Our results are comparable with the increased number of SAE during the first 15 weeks described in the Prednisone, Azathioprine, and N-Acetylcysteine: A Study That Evaluates Response (PAN-THER) trial in IPF patients. 10 In 77 IPF patients treated with combination therapy of prednisone, azathioprine and N-acetylcysteine for 60 weeks, 31 SAE were observed. Approximately 70% of these SAE occurred during the first 15 weeks of high dose prednisone and 30% during the last 45 weeks of low dose prednisone. Historically, before results of the PANTHER trial were published, the starting dose of prednisone treatment in IPF patients was even higher, exceeding 1.0 mg/kg/day. 18 Unfortunately, these studies lack information on dose-related SAE. Our data suggest that a starting dose of >0.3 mg/kg/day could increase SAE in patients with posIPF.
The non-responding patients had more honeycombing on HRCT than responding patients (90% vs 50%). Our results therefore especially discourage the use of prednisone in posIPF patients with honeycombing on HRCT. However, subgroups of female patients and former smokers with focal DIP-like features besides a UIP pattern in the SLB could have some benefit from prednisone treatment. Katzenstein et al. described earlier presence of DIP-like reaction in SLBs with UIP, but did not relate these findings to treatment response. 19 Therapy for IIP patients with a diagnosis of DIP consists of smoking cessation and prednisone treatment. 20, 21 A previous study showed that 90% of 31 DIP patients had significant radiological improvement or increase in partial pressure of arterial oxygen following corticosteroid therapy. 21 Interestingly, in our study, patients with a concomitant focal DIP-like reaction in the SLB who stopped smoking <5 years ago had a significant beneficial effect of prednisone treatment.
This study has important limitations. The retrospective characteristic of this multicentre study in two referral hospitals causes limitations due to absence of data at specific time points and the absence of a control group. Moreover, we had to rely on some PFT data from referring hospitals, resulting in possible variability of PFT. However, despite a number of missing values, accelerated FVC decline after prednisone treatment was clearly observed.
Taken together, our findings suggest that the UIP pattern in SLB is a stronger indicator of underlying pathology than an inconsistent UIP pattern on HRCT. This agrees with the finding of Yagihashi et al. who conducted a retrospective analysis of patients with biopsy-proven UIP from three 'IPF' trials completed before the introduction of the more strict ATS/ERS IPF guidelines in 2011. They found no significant difference in survival between radiology-pathology-discordant (radiological inconsistent UIP) and radiology-pathology-concordant groups, suggesting true IPF in all groups. 4 In current practice, we recommend consideration of a 'working diagnosis of IPF' for patients with posIPF. Further research is required to show whether these patients benefit from anti-fibrotic therapy. In addition, in female patients and patients with a concomitant focal DIP-like reaction in SLB, a low dose of prednisone might still be worth considering, particularly when smoking cessation was relatively recent.
In conclusion, this study provides evidence that patients classified as 'posIPF' according to current international diagnostic guidelines deteriorate on treatment with corticosteroids. We suggest using a provisional working diagnosis of IPF.
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